Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating an $20 price target on Immunomedics after its Q4 results and pipeline update. The analyst says the company offered “minimal updates for its timeline around a potential BLA re-submission” as it continues to work on finalizing the response strategy, but believes that today’s announcement of the resignation of its CEO should not impact the timing of the response.
https://thefly.com/landingPageNews.php?id=2869947
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.